scholarly journals RADIATION DOSE OPTIMIZATION OF BREAST CANCER WITH PROTON THERAPY METHOD USING PARTICLE AND HEAVY ION TRANSPORT CODE SYSTEM

2021 ◽  
Vol 23 (2) ◽  
pp. 79
Author(s):  
Milah Fadhilah Kusuma Fasihu ◽  
Andang Widi Harto ◽  
Isman Mulyadi Triatmoko ◽  
Gede Sutrisna Wijaya ◽  
Yohannes Sardjono
Keyword(s):  
Breast Cancer ◽  
Proton Therapy ◽  
Left Lung ◽  
Optimal Dose ◽  
Heavy Ion ◽  
Left Breast ◽  
High Dose ◽  
Good Precision ◽  
Pencil Beam ◽  
The Right

Radiotherapy is one of the cancer treatments conducted by giving a high dose to the tumor target and minimizing the dose exposed in the healthy organs. One of the methods is proton therapy. Proton therapy is usually used in several breast cancer cases by minimizing the damage in the surrounding tissues due to having good precision. In this study, proton therapy in breast cancer will be simulated. This study aims to identify the optimal dose in breast cancer therapy using proton therapy and to identify the dose exposed in the healthy organs surrounding cancer. This study is PHITS program simulation-based to model the geometry and the components of breast cancer and the surrounding organs. The source of radiation used is proton which is the output of proton therapy with proton/sec firing intensity. The variation in beam modelling towards the dose profile of the tumor used is uniform and pencil beam. The proton energy used is 70 MeV up to 120 MeV. The result of this study shows that the dose from using pencil beam scanning technic of proton therapy for breast cancer is 50.3997 Gy (W) with the total amount of fraction is 25 and the result of dose below the threshold dose in the healthy organs is the skin gets 4.4.0553 Gy per fraction, the left breast gets 0,0011 Gy per fraction, the right breast gets 2.6469 Gy per fractions, the right lung gets 0.0125 Gy per fraction, the left lung gets 0.029 Gy per fraction, the rib gets 0.0179 Gy per fraction, and the heart gets 0.0077 Gy per fraction.

Left Breast Radiotherapy With Multi Fields Hybrid Intensity Modulated Radiotherapy (IMRT) Versus Volumetric Modulated Arc Therapy (VMAT): Balance Between Left Anterior Descending Artery Sparing and Secondary Cancer Induction Risk

2021 ◽  
Author(s):  
Xiaoyong Xiang ◽  
Zhen Ding ◽  
Kailian Kang ◽  
Zhitao Dai ◽  
Wenjue Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Volumetric Modulated Arc Therapy ◽  
Left Lung ◽  
Breast Conserving Surgery ◽  
Left Breast ◽  
High Dose ◽  
Breast Cancer Patients ◽  
Breast Radiotherapy ◽  
Breast Cancer Radiotherapy ◽  
Arc Therapy

Abstract To explore the feasibility of using Volumetric-Modulated Arc Therapy (VMAT) to protect left anterior descending branch (LAD) after breast-conserving surgery for left breast cancer. 15 left breast cancer patients after breast-conserving surgery were selected. 7F-IMRT and 2A-VMAT treatment plans were designed with Varian Eclipse TPS (13.6version). The prescriptions of PTV and PTV Boost were 43.5Gy and 49.5Gy in 15 fractions. The dosimetric parameters, OARs dose sparing and second cancer risk (SCR) were compared between the two plans using a paired t-test. The VMAT plans obtain better PTV conformity and higher mean dose. VMAT plans show a better dose distribution in high dose areas and better sparing of OARs, including left lung, heart, and LAD. The Dmax and Dmean of LAD decreased significantly in VMAT plans. The SCRs of the contralateral lung and breast significantly increased with a higher mean dose. We recommend that contouring and evaluating the dose of LAD and LAD helping structures in left breast cancer radiotherapy. SCR should be evaluated for younger patients.

scholarly journals Radiation dose to the heart with hypofractionation in patients with left breast cancer

2021 ◽  
Vol 2 ◽  
Author(s):  
Budhi Singh Yadav ◽  
Deepak Kumar Das ◽  
Narendra Kumar ◽  
Manphool Singhal ◽  
Ngangom Robert
Keyword(s):  
Breast Cancer ◽  
Radiation Dose ◽  
Organs At Risk ◽  
Breast Conservation ◽  
Left Lung ◽  
Left Breast ◽  
Breast Conservation Surgery ◽  
Study Planning ◽  
Significant Difference ◽  
The Right

Abstract Introduction In this study we compared radiation dose received by organs at risk (OARs) after breast conservation surgery(BCS) and mastectomy in patients with left breast cancer. Materials and methods Total 30 patients, 15 each of BCS and mastectomy were included in this study. Planning Computerised Tomography (CT) was done for each patient. Chest wall, whole breast, heart, lungs, LAD, proximal and distal LAD, and contra lateral breast was contoured for each patient. Radiotherapy plans were made by standard tangent field. Dose prescribed was 40Gy/16#/3 weeks. Mean heart dose, LAD, proximal and distal LAD, mean and V5 of right lung, and mean, V5, V10 and V20 of left lung, mean dose and V2 of contra lateral breast were calculated for each patient and compared between BCS and mastectomy patients using student’s T test. Results Mean doses to the heart, LAD, proximal LAD and distal LAD were 3.364Gy, 16.06Gy, 2.7Gy, 27.5Gy; and 4.219Gy, 14.653Gy, 4.306Gy, 24.6Gy, respectively for mastectomy and BCS patients. Left lung mean dose, V5, V10 and V20 were 5.96Gy, 16%, 14%, 12.4%; and 7.69Gy, 21%, 18% and 16% in mastectomy and BCS patients, respectively. There was no statistical significant difference in the doses to the heart and left lung between mastectomy and BCS. Mean dose to the right lung was significantly less in mastectomy as compared to BCS, 0.29Gy vs. 0.51Gy, respectively (p = 0.007). Mean dose to the opposite breast was significantly lower in patients with mastectomy than BCS (0.54Gy Vs 0.37Gy, p = 0.007). The dose to the distal LAD was significantly higher than proximal LAD both in BCS (24.6Gy Vs 4.3Gy, p = <0.0001) and mastectomy (27.5Gy Vs 2.7Gy, p = <0.0001) patients. Conclusion There was no difference in doses received by heart and left lung between BCS and mastectomy patients. Mean doses to the right lung and breast were significantly less in mastectomy patients.

scholarly journals Bilateral Primary Breast Cancer: A Case Report and Literature Review

2020 ◽  
Author(s):  
Shuyao Fan ◽  
Xidong Gu ◽  
Zhehao Liang ◽  
Yuping Mao ◽  
Changyu Zhou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Cancer ◽  
Left Lung ◽  
Distant Metastases ◽  
Breast Conserving Surgery ◽  
Left Breast ◽  
Cancer History ◽  
Diagnosis And Prognosis ◽  
Systemic Treatments ◽  
The Right

Abstract BackgroundInvasive micropapillary carcinoma (IMPC) and secretory carcinoma of the breast (SCB) are relatively rare types of breast cancer. IMPC is usually associated with high incidence of lymphovascular invasion, lymph node metastasis and poor prognosis. While SCB usually carries a relatively favorable prognosis, cases of axillary and distant metastases have been reported. Clinicians generally adopt systemic treatments based on the histopathological findings of the patients to improve the prognosis, but there is currently no consensus on the optimal treatment for these two types of cancer.Case presentationWe treated a 50‐year‐old woman with lung cancer history who presented with a single lump in each breast. Following bilateral breast-conserving surgery, the diagnosis of SCB of the left breast and IMPC of the right breast was confirmed with immunohistochemistry. It is worth noting that the pathological results of left lung adenocarcinoma centered on micropapillary-type was same as the invasive micropapillary component of right breast.ConclusionsWe reported this case of bilateral primary relatively-rare-form breast cancer for its extremely rare occurrence and there are less than 20 cases of SCB reported worldwide till now. It is also significative to distinguish this primary tumor of right breast from metastatic cancer. Our histopathologic diagnosis and synthetical therapy scheme will provide material for SCB and IMPC. To facilitate the diagnosis and prognosis of such relatively rare tumors, more cases will need to be reported.

scholarly journals Commissioning of a clinical pencil beam scanning proton therapy unit for ultra‐high dose rates (FLASH)

2021 ◽  
Author(s):  
Konrad P. Nesteruk ◽  
Michele Togno ◽  
Martin Grossmann ◽  
Anthony J. Lomax ◽  
Damien C. Weber ◽  
...  
Keyword(s):  
Proton Therapy ◽  
High Dose ◽  
Pencil Beam ◽  
Beam Scanning ◽  
Dose Rates ◽  
Pencil Beam Scanning

Predominance of RAD21 and ERBB2 amplification and progesterone receptor positivity in tumors of the right breast support breast cancer lateralization.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12557-e12557
Author(s):  
Zachary Spigelman ◽  
Jo-Ellen Murphy
Keyword(s):  
Breast Cancer ◽  
Progesterone Receptor ◽  
Cancer Patients ◽  
Breast Tumors ◽  
Left Breast ◽  
Breast Cancers ◽  
Her2 Expression ◽  
Breast Cancer Patients ◽  
The Right ◽  
Chi Square Analysis

e12557 Background: Biologic lateralization broadly impacts breast cancer. Malignancies originating in the left breast compared to the right breast tend to be more frequent, larger and of poorer prognosis. Left breast tumors respond differently to HER2-neu signaling and have lateralized Ki67 expression. In a prior study a right-left asymmetry in the neutrophil/lymphocyte ratio (NLR) of breast cancers was identified (ASCO 2018, e13094). As a follow-up, retrospective analysis of results from comprehensive genomic profiling (CGP) of right and left side breast cancer specimens was performed to determine a potential genomic etiology for the observed NLR lateralization. Methods: Tumors from 43 consecutive breast cancer patients underwent analysis for all classes of genomic alterations by hybrid capture-based CGP (Foundation Medicine). The CGP results from the 25 left- and 18 right-sided breast cancer samples were analyzed along with the histologic grade and status of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. Results: In this cohort of advanced breast cancer patients (stage 3-4), no statistically significant differences in lateralization were identified based on patient age, tumor stage, or frequency of ER or Her2 expression (Table). A predominance of PR positivity (p=0.14 chi square analysis) and amplifications in the ERBB2 (p=0.37) and RAD21 (p=0.08) genes were detected in right side tumors. Conclusions: Together with the prior study, trends in asymmetry based on genomic, pathologic, and immunohistologic differences have been detected in breast cancers, including an increased incidence of ERBB2 and RAD21 amplification in right-side breast tumors in this cohort. The predominance of lower PR positivity in the left breast tumors may be due to preferential hypermethylation, consistent with reports that it mediates biologic lateralization changes, downregulates PR expression, and alters amplification rates. Epigenetic methylation, may contribute to asymmetric breast cancer biology and have implications for therapeutic strategy. Further study is warranted.[Table: see text]

scholarly journals Difficulty Diagnosing a Brain Tumor during Clinical Maintenance of a Complete Response to anti-HER2 Treatments for Metastatic Breast Cancer: A Case Report

2020 ◽  
Vol 13 (3) ◽  
pp. 1311-1316
Author(s):  
Ryoko Semba ◽  
Yoshiya Horimoto ◽  
Atsushi Arakawa ◽  
Yoko Edahiro ◽  
Tomoiku Takaku ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Tumor ◽  
Ductal Carcinoma ◽  
Metastatic Breast ◽  
Stage Iv ◽  
B Cell Lymphoma ◽  
High Dose ◽  
Her2 Positive ◽  
Stage Iv Breast Cancer ◽  
The Right

A 46-year-old woman with erythema of the right breast presented to our hospital and was diagnosed with stage IV breast cancer (HER2-positive invasive ductal carcinoma). She received 4 courses of anthracycline-based regimens and 4 courses of trastuzumab + pertuzumab + docetaxel (Tmab + Pmab + DTX). Since she responded well to these therapies, only Tmab + Pmab was continued thereafter. Twenty-three months after starting treatment, she developed a headache. A tumor was identified in the right temporal lobe. Craniotomy was performed for definitive diagnosis. Intraoperative pathological assessment suggested the tumor to be brain metastasis of breast cancer. However, the final pathological diagnosis was diffuse large B-cell lymphoma of central nervous system (DLBCL-CNS) based on re-assessment with immunohistochemical examinations. Therefore, the Tmab + Pmab was discontinued, and 6 courses of high-dose methotrexate therapy were administered. This case highlights the importance of considering rare entities, such as DLBCL, when diagnosing a solitary brain tumor in a patient with a primary cancer, based on imaging and pathological findings.

Randomized, Controlled, Dose-Range Study of Ro 25-8315 Given Before and After a High-Dose Combination Chemotherapy Regimen in Patients With Metastatic or Recurrent Breast Cancer Patients

2002 ◽  
Vol 20 (1) ◽  
pp. 24-36 ◽  
Author(s):  
P. Viens ◽  
C. Chabannon ◽  
P. Pouillard ◽  
M. Janvier ◽  
W. Brugger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Progenitor Cell ◽  
Chemotherapy Regimen ◽  
Single Injection ◽  
Optimal Dose ◽  
High Dose ◽  
Breast Cancer Patients ◽  
Number Of Patients ◽  
Cell Mobilization

PURPOSE: To evaluate the safety, pharmacokinetics, and efficacy of three different dose levels of pegylated granulocyte colony-stimulating factor (Ro 25-8315) on progenitor cell mobilization and hematologic recovery in cancer patients. PATIENTS AND METHODS: Breast cancer patients (n = 36) were randomly assigned to receive before (part I) and after (part II) chemotherapy either a single-dose injection of Ro 25-8315 (20 μg/kg, n = 9; 60 μg/kg, n = 9; 100 μg/kg, n = 10) or a standard daily dose of filgrastim (part I, 10 μg/kg/d; part II, 5 μg/kg/d) (control group, n = 8). RESULTS: Overall, Ro 25-8315 was well tolerated. In part I, more progenitor cell mobilization was observed with Ro 25-8315 100 μg/kg. The peak of circulating CD34+ cells was obtained at day +5 in the four groups, and the absolute neutrophil count (ANC) returned to less than 20 × 109/L by day +15. In part II, high levels of circulating CD34+ cells (> 20 cells/μL) were obtained in all four groups. The chemotherapy-induced neutropenia (< 1 × 109/L) was similar in the four groups. Ro 25-8315 100 μg/kg was more effective than filgrastim in reducing the number of patients with an ANC less than 0.5 × 109/L on day +12 after chemotherapy. CONCLUSION: A single injection of Ro 25-8315 100 μg/kg might be the optimal dose for steady-state peripheral-blood progenitor cell mobilization. A single injection of 20, 60, or 100 μg/kg could be as efficient as daily administration of filgrastim to correct chemotherapy-induced cytopenia. The optimal dose of Ro 25-8315 should be determined according to the planned chemotherapy regimen.

scholarly journals Wearable infra-red pre-screening smartbra for early detection of breast cancer

2020 ◽  
Vol 39 (2) ◽  
pp. 506-513
Author(s):  
E.O. Nwoye ◽  
O.P. Fidelis ◽  
O. Ogunsolu
Keyword(s):  
Breast Cancer ◽  
Early Detection ◽  
High Sensitivity ◽  
Left Breast ◽  
Absolute Temperature ◽  
University Teaching ◽  
Cancer Early Detection ◽  
Infra Red ◽  
The Difference ◽  
The Right

Breast cancer is the most common cancer in women worldwide, comprising 16% of all female cancers and early diagnosis remains an important detection strategy. The aim of this study was to design and implement a user-friendly SmartBra. An infra-red (IR) imaging sensor was deployed to determine the temperature profile of the breast for this application. The device was tested with approval from the Health Research Ethics  Committee of the Lagos University Teaching Hospital using healthy persons and persons already diagnosed with different stages of breast cancer. The results showed high sensitivity and specificity with good intra-examiner reliability for absolute values of mean temperature for the right breast and very good reproducibility for the left breast. Data for healthy participants revealed that the difference in absolute temperature between the left and right breast was less than 1oC, while that of the sick (cancer) participants indicated values greater than 1oC. The device is safe and easy to use and therefore can serve as an adjunct diagnostic device for early detection of breast cancer. Keywords: breast cancer, early detection, infra-red thermography, mammography.

scholarly journals A Case of Atypical Intraductal Papilloma of the Right Breast with Left Breast Cancer

1979 ◽  
Vol 18 (2) ◽  
pp. 183-188
Author(s):  
Sunayo KATAYAMA ◽  
Kota YATSUKA ◽  
Yasuyuki SASAGURI ◽  
Koji IRIE ◽  
Shyoko SATO ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Left Breast ◽  
Intraductal Papilloma ◽  
The Right
Sign in / Sign up

Export Citation Format

Share Document